Myocardial involvement in children with post-COVID multisystem inflammatory syndrome: a cardiovascular magnetic resonance based multicenter international study—the CARDOVID registry

Table 5 CMR Characteristics at baseline

	Total n = 111	Myocarditis (Group 1) (n = 20)	No myocarditis (Group 2) (n = 91)	p-value
Delay symptom onset-CMR, days (n = 109)	28 (19–47)	27 (17–34)	28 (19–50)	0.330
T2 BB	18/110 (16)	11/20 (55)	7/90 (8)	< 0.001
LGE	22/110 (20)	18/20 (90)	0/90	< 0.001
LVEF (%)	58 (55–63)	59 (51–63)	58 (55–63)	0.524
LVEF < 55% (no. of pts)	21/105 (20)	5/19 (26)	16/86 (19)	0.527
LVEDVI (ml/m²)	77.4 ± 15.3	76.8 ± 15.3	77.6 ± 15.4	0.853
LVESVI (ml/m²)	32 (27–38)	34 (25–43)	32 (27–37)	0.464
RVEF (%)	57.3 ± 6.2	56.4 ± 7.8	57.5 ± 5.8	0.519
RVEDVI (ml/m²)	74.0 ± 14.3	77.1 ± 12.4	73.2 ± 14.7	0.325
RVESVI (ml/m²)	33.2 ± 9.6	35.6 ± 9.8	32.7 ± 9.6	0.290
Pericardial effusion (no. pts)	18/89 (20)	5/10 (50)	13/79 (16)	0.026

Bold p values were significative
Values are presented as absolute numbers (%), medians (IQR) or mean (± sd) as appropriate. The denominator for each field is reflective of the total number of available data entry points. CMR cardiac magnetic resonance, T2 BB T2 black blood sequence, LGE late gadolinium enhancement, LVEF left ventricular ejection fraction, LVEDVI left ventricular end diastolic volume indexed for body surface area (BSA), LVESVI left ventricular end systolic volume indexed for BSA, RVEF right ventricular ejection fraction, RVEDVI right ventricular end diastolic volume indexed for BSA, RVESVI right ventricular end systolic volume indexed for BSA, pts patients

ISSN: 1532-429X